For this reason, there has been some hope that laboratory changes related to paraneoplastic syndromes may help diagnose at least some early-stage lung cancer. Paraneoplastic syndromes are most ...
Hong Kong-listed Shanghai Henlius Biotech Inc, a subsidiary of Fosun Pharma, announced on Wednesday that its anti-PD-1 mAb, ...
GlobalData on MSN3d
MAIA’s lung cancer therapy 99% more likely to improve OS over chemo aloneA treatment for patients living with advanced non-small cell lung cancer (NSCLC) who failed two or more standard-of-care (SOC ...
The European Commission on Feb. 5 cleared Shanghai Henlius Biotech Inc.’s serplulimab (HLX-02) under the brand name of Hetronifly as a first-line combination therapy with carboplatin and etoposide to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback